Racial and ethnic differences in the severity, prognosis, and mortality of multiple sclerosis (MS) have been the focus of ...

The stock's fall snapped a four-day winning streak.

Biogen Inc. and Biogen MA Inc. (“Biogen”) filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief ...

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

Samsung Biologics spins off Samsung Bioepis Holdings to enhance competitiveness Samsung Bioepis Holdings aims to streamline ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Samsung Biologics separates CDMO and biosimilars with new holding company Samsung Bioepis Holdings aims to enhance corporate ...

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...